Knight Therapeutics Inc. GUD.TO
Nov 5, 2026, 2:44 PM EST
- YTD
- +92.56%
- 1 year
- +99.49%
- Market cap
- 1.14B
- Revenue (ttm)
- 547.31M
- Profit margin
- 2.72%
- EPS (ttm)
- 0.15
- Shares out
- 98.23M
- P/E ratio
- 77.67
- Forward P/E
- 43.46
- YTD return
- +92.56%
- 1-year return
- +99.49%
- Volume
- 122.33K
- Avg volume
- 78.58K
- Open
- 11.84
- Previous close
- 11.30
- Day's range
- 11.29 – 11.86
- 52-week range
- 5.76 – 11.70
- Beta
- 0.02
- Price target
- 11.65 (+0.0%)
3M +2.17 (+22.84%)
Key statistics
- Enterprise value
- 1.02B
- PEG ratio
- 0.00
- Price / sales
- 2.03
- Price / book
- 1.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 34.30%
- Free cash flow
- 63.38M
- Total cash
- 121.17M
- Total debt
- 34.28M
- Return on equity
- 1.91%
- Short % of float
- 0.00%
- 50-day average
- 10.48
- 200-day average
- 8.58
Analyst view
- Target (low)
- 10.80
- Target (mean)
- 11.65
- Target (high)
- 14.00
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.01.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 6, 2024 | Raymond James | main | Outperform | Outperform |
About Knight Therapeutics Inc.
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- knighttx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on GUD.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bosano (Leopoldo Agustin) | Senior Officer of Issuer | Exercise of rights | Mar 22, 2026 | 19,476 |
| Emblem (Susan Caroline) | Senior Officer of Issuer | Acquisition or disposition under a purchase/ownership plan | Sep 14, 2026 | 46,311 |
| Gale (James) | Director of Issuer | Exercise of options | Apr 12, 2026 | 52,997 |
| Goodman (Jonathan Ross) | Director of Issuer | Acquisition or disposition under a purchase/ownership plan | Sep 14, 2026 | 1,036,111 |
| Khouri, Amal | Senior Officer of Issuer | Acquisition or disposition under a purchase/ownership plan | Sep 14, 2026 | 200,810 |
| Lande (Robert Nathaniel) | Director of Issuer | Acquisition or disposition in the public market | May 13, 2026 | 223,178 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Artisan Partners Funds Inc.-Artisan International Explorer Fund | 1.41% | 1,390,451 | 15.71M | Jun 29, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT. | 0.86% | 841,363 | 9.51M | Jul 30, 2026 |
| DFA INVESTMENT TRUST CO-The Canadian Small Company Series | 0.49% | 484,400 | 5.47M | Jul 30, 2026 |
| DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT. | 0.38% | 372,491 | 4.21M | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional International Small Cap Value ETF | 0.31% | 304,699 | 3.44M | Jul 30, 2026 |
| Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund | 0.25% | 246,614 | 2.79M | Jul 30, 2026 |